Research and Markets (http://www.researchandmarkets.com/research/c847f0/expanding_applicat) has announced the addition of the "Expanding Applications of Personalized Medicine: Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach" report to their offering.
Over the past decade, several significant advances in targeted therapies have improved the ability to treat certain cancers, the most notable early successes been trastuzumab in breast cancer and imatinib in chronic myelogenous leukemia. Recently, several important breakthroughs have occurred, including the identification of a mechanism of resistance to EGFR monoclonal antibodies in colorectal cancer, which may be followed by further predictive tests leading to a reduction in the use of ineffective therapies.
'Expanding Applications of Personalized Medicine' is a report that provides an in-depth analysis of current applications in personalized medicine, and highlights future opportunities and clinical advances. Ongoing research into predictive biomarkers of resistance/efficacy and how they will optimize treatment and improve patient outcomes are explored. This report provides a unique summary of ongoing clinical trials incorporating personalized medicine approaches, based on an analysis of over 6,000 clinical studies. Although investment in personalized medicine is beginning to show valuable results, its integration into routine clinical practice has been slow and it currently does not impact the care of the vast majority of patients. To widen the benefits of personalized medicine over the next ten years, several obstacles need to be overcome, including increased regulatory burden, lack of reimbursement, demonstration of clinical utility and integration into drug development.
Key findings